MIAMI, FLORIDA / ACCESS Newswire / December 16, 2025 / AstraZeneca, Eastman, Kraft Heinz, and P&G have been recognized for ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's Enhertu in combination with Roche ...

Shares of Compugen Ltd. (NASDAQ:CGEN) rose 12.8% in premarket trading on Wednesday after the company unveiled a strategic ...

Shares of Compugen (CGEN) added ~16% in the premarket on Wednesday after the Israel-based biotech announced an agreement with ...

Israeli drug discovery and development company Compugen (Nasdaq: CGEN; TASE: CGEN) today announced changes in its ...

AstraZeneca's fair value estimate has nudged up to about $150.26 from roughly $146.44, even as the long run revenue growth ...

At this year's ASH congress, the results of the phase 1b/2 DURGA-1 of AZD0120 – a dual BCMA and CD19-directed CAR-T therapy – ...

AstraZeneca and Daiichi Sankyo got U.S. approval to expand the label of their jointly developed Enhertu drug in combination with another medicine as an initial treatment for a type of breast cancer.

The move would onshore production of its rare disease products at an existing facility in Frederick and build a clinical research drug factory in Gaithersburg.

AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about ...

Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) is indicated for the treatment ...

Home to 4.8 billion people or 60 percent of the world’s population, Asia accounts for 50 percent of the global cancer ...